MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer

Inclusion Criteria: 1. 18 to 70 Years Old, female; 2. Expected survival \> 12 weeks; 3. Clinical performance status of ECOG score 0-2; 4. Patients who have previously been treated with second- line or more lines of standard treatment are not effective (No remission or recurrence after remission); 5. At least one measurable tumor foci according to RECIST standard 1.1 ; 6. Positive Mesothelin expression in tumor tissues; 7. Creatinine ≤ 1.5×ULN; 8. ALT and AST ≤ 3×ULN; 9. Total bilirubin ≤ 2×ULN; 10. Hemoglobin≥90g/L; 11. Absolute counting of neutrophils≥1000uL ; 12. Absolute counting of lymphocytes\>0.7×10\^9/L; 13. Counting of Platelet≥75000/uL; 14. The venous access required for collection can be established without contraindications for leukocyte collection; 15. Able to understand and sign the Informed Consent Document. Exclusion Criteria: 1. Accompanied by other uncontrolled malignant tumors; 2. Active hepatitis B, hepatitis C, syphilis, HIV infection; 3. Suffering severe cardiovascular or respiratory disease; 4. Any other diseases could affect the outcome of this trial; 5. Any affairs could affect the safety of the subjects or outcome of this trial; 6. Pregnant or lactating women, or patients who plan to be pregnancy during or after treatment; 7. There are active or uncontrollable infections (except simple urinary tract infections or upper respiratory tract infections) that require systemic therapy 14 days or 14 days prior to assignment; 8. Patients who are accounted by researchers to be not appropriate for this test; 9. Received CAR-T treatment or other gene therapies before assignment; 10. Subject suffering disease affects the understanding of informed consent or comply with study protocol.